Initial Technology Transfer. Within ​ Business Days following the Effective Date, Beam shall, at no additional cost to Sana, provide a technology transfer to Sana or its designee of # the ​, # ​ described or specified in or generated under the Technology Transfer Plan; and # the other information and assistance specifically described in Exhibit E (the “Initial Technology Transfer Plan”). ​ shall be responsible for the internal and out-of-pocket costs incurred in connection with Initial Technology Transfer Plan in accordance with the budget (the “Initial Technology Transfer Budget”) set forth in Exhibit E. In addition, the Parties may from time to time agree in writing certain other technology transfer activities. Any such activities will be set forth in a written plan (each such plan, including the Initial Technology Transfer Plan, a “Technology Transfer Plan”) that includes the timeline and details of all technology transfer activities to be conducted thereunder. In addition, with respect to each Technology Transfer Plan, the Parties will agree in writing in advance upon a mutually agreed budget ​ incurred in connection with any such Technology Transfer Plan (each such budget, including the Initial Technology Transfer Budget, a “Technology Transfer Budget”).

At any time upon the request of Client ​ of a Product Agreement for any reason, Patheon will provide assistance as reasonably requested by Client to transfer part or all of Client’s manufacturing process, know-how and analytical testing methodology for the Product to Client or Client’s third-party designee (“Technology Transfer”) to assist Client to manufacture the Product. Patheon will ensure that the Technology Transfer is performed on its behalf by personnel skilled in providing the Manufacturing Services. The Technology Transfer will include provisions of the master batch record all other documents, information and knowledge as necessary or appropriate to transfer work performed as part of the Manufacturing Services by Patheon and may include reasonable consultation, meetings and travel to another site. Patheon will also disclose to Client any Patheon Intellectual Property that is reasonably required to manufacture the Product and grant to Client an irrevocable, fully paid, sublicensable license to exploit the Patheon Intellectual Property as reasonably required to manufacture the

Initial Technology Transfer. Within the time periods set forth in a technology transfer plan to be agreed by the Parties within sixty (60) days after the Effective Date, AGTC shall transfer to LICENSEE at ​’s sole expense, to the extent not already transferred to LICENSEE under the Collaboration Agreement, a true and complete copy as reasonably practicable of # data embodying any ​ Manufacturing Know-How, # other tangible embodiments of ​ Manufacturing Know-How and # documentation necessary or useful to evaluate the Materials including # data safety sheets, # history (provenance) of cell lines and viral seed stocks, # development reports (e.g., process development, specifications, stability data for cell and viral banks, suspension and serum-free media adaptation of cell lines, media development, viral

Technology Transfer. Upon written request of Apellis, [[Bachem CH:Organization]] shall promptly (within no more than ​ following receipt of such request) initiate transfer to Apellis in writing of all technical information related to the Manufacture of Drug Substance pursuant to this Agreement, including, but not limited to, information concerning ​ under this Agreement. Apellis shall be entitled to use and ​ the Drug Substance or Product. Apellis agrees to ​ transfer including, but not limited to, ​. Upon written request by Apellis, [[Bachem CH:Organization]] shall ​ pursuant to this Agreement, including information concerning ​. To the extent that ​ pursuant to this Section 9.4 to be ​, Apellis shall ​ and the Parties shall ​.

. Promptly following the Effective Date, [[DURECT:Organization]] shall provide electronic copies to INNOCOLL, for no additional consideration or cost reimbursement for the non-physical transfer, of all:

Technology Transfer. Upon successful completion of the Development Plan and pilot scale in Phase III, the initial tech transfer to Licensee will occur with each party bearing their own costs and Licensor shall transfer the Production Strain(s) and sufficient know-how and Confidential Information to enable Licensee to use the Production Strains to develop and commercialize the Product(s) in the Field. If additional support is requested, Licensee shall pay for Licensor’s time and expenses in transferring the Production Strains and related Technology at Licensor’s standard full-time equivalent (“FTE”) rates for Licensor personnel having the knowledge and experience to affect the transfer. During the additional technology transfer and as needed thereafter, Licensee shall reimburse Licensor’s costs to # ship samples and Production Strains; # provide technical support to enable Licensee to grow the Production Strains to produce the Product; and # expenses and costs for related travel, if applicable.

Technology Transfer. The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the Facility, including implementing the technology transfer plan set forth in Project Plan. Customer shall fully support such technology transfer as reasonably requested by [[Lonza:Organization]].

Technology Transfer. Promptly following the Effective Date, ITEOS shall transfer and deliver to GSK (in order to enable GSK to practice under the licenses granted to GSK under Section 9.1 (License Grant to GSK)), Know-How within the ITEOS Technology (including Materials) to enable GSK to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products as contemplated under this Agreement.

Initial Technology Transfer. Equinox represents and warrants, and subject to such representation and warranty EyePoint acknowledges and agrees that, prior to the Effective Date, Equinox has transferred and delivered to EyePoint all tangible embodiments of the Equinox Know-How (other than Regulatory Materials and the Manufacturing Know-How) in its possession or in existence on or prior to the Effective Date, including clinical data arising from Equinox’s development activities prior to the Effective Date. For a period of twelve (12) months after the Effective Date, Equinox shall use Commercially Reasonable Efforts, at EyePoint’s reasonable request and expense, to provide technical assistance to enable the use of the transferred Equinox Know-How, and any updates to the Equinox Know-How that may occur up to twelve (12) months after the Effective Date.

Initial Technology Transfer. As soon as possible after the Effective Date, but no later than ​ months from the Effective Date (as such period may be extended by mutual written agreement of the Parties), aTyr, at its cost and expense, will complete a transfer to Kyorin of the aTyr Licensed Know-How in existence as of the Effective Date (including, to the extent applicable and in existence and Controlled by aTyr or its Affiliates as of the Effective Date, study reports, batch records, vendor information, validation documentation, pre-clinical data, analyses, manufacturing data, and applicable reference standards used in analytical testing of the Licensed Product) as described in the technology transfer plan to be mutually agreed by the Parties and to be attached as a schedule to the Letter Agreement setting forth the details of such aTyr Licensed Know-How to be transferred and the timing of such transfer (the “Technology Transfer Plan”).